Skip to content

Effect of Recording Duration on Heart Rate Variability During taVNS

Effect of Recording Duration on Heart Rate Variability During Transcutaneous Auricular Vagus Nerve Stimulation: A Randomized, Sham-Controlled Crossover Study

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07526415
Acronym
taVNS-HRV
Enrollment
40
Registered
2026-04-13
Start date
2026-05-01
Completion date
2026-09-15
Last updated
2026-04-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Volunteers

Keywords

Transcutaneous Auricular Vagus Nerve Stimulation, taVNS, Autonomic Nervous System

Brief summary

This study aims to evaluate how different heart rate variability (HRV) recording durations reflect autonomic nervous system responses during transcutaneous auricular vagus nerve stimulation (taVNS) in healthy adults. In a randomized, sham-controlled crossover design, participants will attend two separate sessions and receive both active taVNS and sham stimulation in randomized order. During each session, a continuous 10-minute HRV recording will be obtained, and 1-minute, 5-minute, and 10-minute analysis windows will be compared. Blood pressure and pulse will also be measured before and after stimulation. The study will investigate whether shorter or longer HRV recording durations provide results comparable to the standard 5-minute recording and which duration most reliably detects autonomic changes during taVNS.

Detailed description

The vagus nerve plays a central role in autonomic regulation, and heart rate variability (HRV) is a widely used noninvasive marker of autonomic nervous system activity. Transcutaneous auricular vagus nerve stimulation (taVNS) has increasingly been used in experimental and clinical research as a noninvasive method to modulate vagal activity. Although previous studies suggest that taVNS may influence parasympathetic activity, HRV measurement duration remains an important methodological issue. Standard short-term HRV analysis is commonly based on 5-minute recordings, but ultra-short and longer recordings are also used, and their validity during taVNS has not been sufficiently clarified. This study is designed to determine whether different HRV recording durations provide comparable and reliable information during taVNS. The study will use a randomized, sham-controlled crossover design. Healthy adult participants will attend two sessions separated by a washout period of 48 to 72 hours. In one session, participants will receive active taVNS; in the other, they will receive sham stimulation. The order of sessions will be randomized. During each session, HRV data will be collected continuously for 10 minutes using a Polar H10 chest strap. From this single uninterrupted recording, 1-minute, 5-minute, and 10-minute analysis windows will be derived. HRV parameters from time-domain and frequency-domain analyses will be calculated. Blood pressure and pulse will be measured before and after the intervention using an automated upper-arm blood pressure monitor. Active taVNS will be applied to the cymba conchae region of the ear using commonly reported stimulation parameters. Sham stimulation will be delivered with the same device and similar sensory conditions, but at a non-vagal ear location to minimize physiologic vagal effects. This design is intended to control for nonspecific sensory and expectation-related effects. The primary objective is to assess whether the standard 5-minute HRV recording during taVNS detects autonomic effects compared with sham stimulation. Secondary objectives are to examine the agreement between 1-minute, 5-minute, and 10-minute HRV measurements and to evaluate whether shorter or longer recordings provide additional methodological value. The relationship between HRV findings and hemodynamic responses, including blood pressure and pulse, will also be explored. This study may help identify the most appropriate HRV recording duration for future taVNS research and contribute to methodological standardization in this field.

Interventions

DEVICETranscutaneous Auricular Vagus Nerve Stimulation

Active transcutaneous auricular vagus nerve stimulation will be applied bilaterally to the cymba conchae region of the ear using a transcutaneous stimulation device. Stimulation will be delivered for 10 minutes with a frequency of 25 Hz, a pulse width of 200 to 300 microseconds, and an individually adjusted intensity that is clearly perceptible but not painful. Heart rate variability will be recorded continuously during the intervention.

DEVICESham Stimulation

Sham stimulation will be delivered for 10 minutes using the same transcutaneous stimulation device and similar stimulation settings as the active intervention, but the stimulation will be applied to a non-vagal ear region, such as the earlobe or helix, to minimize physiologic vagal effects while maintaining similar sensory input. Heart rate variability will be recorded continuously during the intervention.

Sponsors

Sinop University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Investigator, Outcomes Assessor)

Masking description

The study will use partial blinding. The investigator performing physiologic measurements and the researcher responsible for statistical analysis will be blinded to intervention assignment. Data will be analyzed using coded datasets, and group identities will be revealed only after completion of the analyses. The researcher delivering the intervention cannot be blinded because active taVNS and sham stimulation require different application sites.

Intervention model description

A randomized, sham-controlled crossover design will be used. Each participant will attend two separate sessions and receive both active transcutaneous auricular vagus nerve stimulation (taVNS) and sham stimulation in randomized order, with a 48- to 72-hour washout period between sessions. Continuous 10-minute heart rate variability recordings will be obtained during each intervention session.

Eligibility

Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy volunteers aged 18 to 40 years * Able and willing to provide informed consent * Able to tolerate active transcutaneous auricular vagus nerve stimulation and sham stimulation * Able to comply with study instructions, including restrictions related to caffeine, nicotine, and heavy exercise before assessment * No condition preventing heart rate variability, blood pressure, or pulse measurements

Exclusion criteria

* Diagnosed cardiovascular disease, arrhythmia, or pacemaker use * History of neurologic disease that may affect autonomic nervous system function * Regular use of medications that may affect heart rate variability or autonomic responses, including beta blockers, antiarrhythmics, or anticholinergic drugs * Active ear infection, dermatologic lesion, or any ear condition that may interfere with stimulation * Marked pain, discomfort, or intolerance during stimulation * Acute infection, fever, or other acute health problem on the measurement day * Heart rate variability data that cannot be evaluated because of excessive motion artifact

Design outcomes

Primary

MeasureTime frameDescription
Difference in 5-minute lnRMSSD During Active taVNS Compared With Sham StimulationDuring the 10-minute intervention period at each study sessionThe primary outcome is the between-condition difference in 5-minute heart rate variability, assessed by lnRMSSD derived from the continuous RR interval recording obtained during the 10-minute intervention period. The 5-minute analysis window is the prespecified standard short-term HRV measure used to compare active transcutaneous auricular vagus nerve stimulation with sham stimulation.

Secondary

MeasureTime frameDescription
Agreement Between 1-minute and 5-minute HRV Measurements During Active taVNSDuring the 10-minute intervention period at each active taVNS sessionAgreement between ultra-short 1-minute and standard 5-minute HRV measurements obtained from the same continuous RR recording during active taVNS will be assessed using predefined agreement analyses.
Comparison of 10-minute and 5-minute HRV Measurements During Active taVNSDuring the 10-minute intervention period at each active taVNS sessionHRV parameters derived from 10-minute and 5-minute analysis windows of the same continuous RR recording during active taVNS will be compared to determine whether the longer recording provides additional physiologic sensitivity or discriminatory value.
Effect of Recording Duration on HRV Differences Between Active taVNS and Sham StimulationDuring the 10-minute intervention period at each study sessionDifferences between active taVNS and sham stimulation will be evaluated across 1-minute, 5-minute, and 10-minute HRV analysis windows to determine whether recording duration influences the detection of autonomic effects.
Change in Systolic and Diastolic Blood Pressure After Active taVNS Compared With Sham StimulationImmediately before and immediately after each 10-minute intervention sessionSystolic and diastolic blood pressure will be measured before and immediately after each intervention session to assess hemodynamic responses to active taVNS and sham stimulation.
Change in Pulse Rate After Active taVNS Compared With Sham StimulationImmediately before and immediately after each 10-minute intervention sessionPulse rate will be measured before and immediately after each intervention session to assess hemodynamic responses to active taVNS and sham stimulation.

Countries

Turkey (Türkiye)

Contacts

CONTACTSefa Haktan Hatık, PhD
haktanhtk@gmail.com+90 368 271 55 28

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 17, 2026